司库奇尤单抗及308 nm准分子光治疗中重度斑块型银屑病的短期疗效对比

目的 观察司库奇尤单抗及308 nm准分子光治疗中重度斑块型银屑病的短期疗效。方法 回顾性分析芜湖市第一人民医院皮肤科门诊2020年5月至2022年6月收治的53例中重度斑块型银屑病患者临床资料，根据治疗方式不同分为治疗组（采用司库奇尤单抗治疗，33例）、对照组（采用308 nm准分子光治疗，20例）。比较两组治疗前后银屑病皮损面积和严重程度指数（PASI）差异。结果 治疗组治疗前后PASI差值明显高于对照组，差异有统计学意义（P<0.05）；两组PASI分值在治疗后均有改善，治疗组患者达到PASI 50、PASI 75、PASI 90的比例分别为91%、52%、21%，对照组达到PASI 50的患者为45%，其余均未达PASI 50。治疗组PASI50优于对照组，差异有统计学意义（P<0.05）。结论 司库奇尤单抗治疗中重度斑块型银屑病的疗效优于308 nm准分子光。

Comparison of short-term curative effect of Secukinumab and 308 nm excimer light for moderate to severe plaque psoriasis

Objective To observe the short-term efficacy of Secukinumab and 308 nm excimer light in the treatment of moderate to severe plaque psoriasis. Methods A total of 53 outpatients from the Department of Dermatology of the First People''s Hospital of Wuhu City from May 2020 to June 2022 were selected, all of whom were diagnosed as moderate to severe plaque psoriasis. According to the treatment methods, the patients were divided into the treatment group(33 cases treated with Secuchiumab) and the control group(20 cases treated with 308 nm excimer light). After two months of treatment,the psoriasis area and severity index(PASI) were compared between the two groups to evaluate the difference in efficacy between the two treatments. Results The PASI difference before and after treatment in the treatment group was significantly higher than that in the control group,and the difference was statistically significant(P<0.01). PASI score in both groups decreased after treatment,91%, 52% and 21% of patients in the treatment group reached PASI 50, PASI 75 and PASI 90, respectively, while in the control group, 45% of patients reached PASI 50, and the rest did not. PASI 50 in the treatment group was better than that in the control group, and the difference was statistically significant(P<0.05). Conclusions The efficacy of Secukinumab in the treatment of moderate to severe plaque psoriasis is better than that of 308 nm excimer light.